Tanureet Arora
Hospitalist · Rochester, NYNPI 1912382201
Payments from drug & device makers
Across 75 payments — averaging $19.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$138
- Xeris Pharmaceuticals, Inc.$127
- Merck$119
- Lilly USA, LLC$108
- Medtronic$82
- Dexcom, Inc.$82
- plus $771 from 25 others
What the payments were for
- Food & beverage$1,37296%
- Education$544%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 9 | $138 |
| Xeris Pharmaceuticals, Inc. | 6 | $127 |
| Merck | 7 | $119 |
| Lilly USA, LLC | 7 | $108 |
| Medtronic | 1 | $82 |
| Dexcom, Inc. | 4 | $82 |
| Amgen | 5 | $78 |
| AbbVie | 3 | $59 |
| Boehringer Ingelheim | 4 | $58 |
| Pacira Pharmaceuticals Incorporated | 2 | $56 |
| Johnson & Johnson | 3 | $53 |
| Averitas Pharma Inc. | 2 | $43 |
| Mannkind Corporation | 1 | $43 |
| Exact Sciences | 2 | $36 |
| GSK | 2 | $32 |
| Pfizer | 2 | $31 |
| Arteriocyte Medical Systems, Inc. | 1 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Kyowa Kirin, Inc. | 1 | $23 |
| Nevro Corp. | 1 | $22 |
| BETA Bionics, Inc. | 1 | $22 |
| Ascendis Pharma Endocrinology Inc | 1 | $19 |
| IBSA Pharma Inc. | 1 | $18 |
| Ionis Pharmaceuticals, Inc. | 1 | $18 |
| Recordati_rare_diseases_inc. | 1 | $18 |
| Dynavax Technologies Corporation | 1 | $17 |
| Neurocrine Biosciences, Inc. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Sequel Med Tech, LLC | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $13 |
How this compares
$1,426 in reported general payments places this provider in the 90th percentile of 1,860 hospitalist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 224 | $361,559 |
| JardianceEmpagliflozin | 160 | $204,374 |
| MounjaroTirzepatide | 106 | $181,540 |
| OzempicSemaglutide | 112 | $173,095 |
| JanuviaSitagliptin Phosphate | 87 | $115,411 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 54 | $89,070 |
| FarxigaDapagliflozin Propanediol | 46 | $62,384 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $48,886 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 65 | $39,364 |
| Humalog Kwikpen U-100Insulin Lispro | 83 | $36,456 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 201 | $36,449 |
| Tresiba Flextouch U-200Insulin Degludec | 32 | $35,504 |
| Tresiba Flextouch U-100Insulin Degludec | 44 | $31,908 |
| Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro | 55 | $29,525 |
| HumalogInsulin Lispro | 78 | $27,835 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Humalog Mix 75-25 | $108 | $578,650423 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy | $58 | $230,600188 claims |
| Novo NordiskOzempic, Novolog | $138 | $178,776126 claims |
| MerckJanuvia, Janumet, Janumet Xr | $119 | $154,476128 claims |
| AbbVieSynthroid | $59 | $5,701102 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,860 hospitalist providers in New York.
Other hospitalist in Rochester
- Nelson Chan-HungRochester$445K
- Saadia SheraziRochester$102K
- Salman AzimRochester$88K
- Farrukh AbbasRochester$84K
- Venkata Satish PendelaRochester$9K
- Amar MunsiffRochester$7K
- Bryan TanRochester$5K
- Megan CoxRochester$5K
- Mark GoldinNew Hyde Park$666K
- Zainab Mogul-AshrafMiddletown$393K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.